Axsome Therapeutics, Inc. $AXSM Shares Sold by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 58.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,888 shares of the company’s stock after selling 8,183 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Axsome Therapeutics were worth $1,086,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Axsome Therapeutics by 14.9% during the second quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock worth $85,000 after purchasing an additional 45 shares during the period. Concurrent Investment Advisors LLC boosted its holdings in Axsome Therapeutics by 4.7% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,739 shares of the company’s stock valued at $426,000 after purchasing an additional 78 shares during the last quarter. Assetmark Inc. boosted its holdings in Axsome Therapeutics by 7.2% in the 1st quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after purchasing an additional 79 shares during the last quarter. Allworth Financial LP grew its stake in shares of Axsome Therapeutics by 5.7% in the 2nd quarter. Allworth Financial LP now owns 1,566 shares of the company’s stock valued at $383,000 after buying an additional 84 shares during the period. Finally, Inceptionr LLC grew its stake in shares of Axsome Therapeutics by 3.2% in the 1st quarter. Inceptionr LLC now owns 4,060 shares of the company’s stock valued at $686,000 after buying an additional 126 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $144.37 on Friday. Axsome Therapeutics, Inc. has a twelve month low of $123.00 and a twelve month high of $260.19. The stock’s fifty day simple moving average is $172.78 and its 200-day simple moving average is $196.98. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.38. The firm had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. Axsome Therapeutics’s revenue was up 51.9% compared to the same quarter last year. During the same period last year, the business posted ($0.94) earnings per share. On average, analysts expect that Axsome Therapeutics, Inc. will post -2.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Needham & Company LLC raised their price target on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Royal Bank Of Canada decreased their price objective on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating on the stock in a report on Tuesday, November 3rd. Guggenheim lowered their price objective on Axsome Therapeutics from $275.00 to $250.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Mizuho cut their target price on Axsome Therapeutics from $284.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, November 4th. Finally, Deutsche Bank reduced their target price on Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $267.58.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the sale, the chief operating officer owned 10,000 shares in the company, valued at $2,086,500. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.60% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.